This week will have moderate activity by the U.S. Food and Drug Administration (FDA). Although they jumped the gun on Regeneron and Sanofi’s cancer drug, there are still plenty of other decisions being made this week. Here’s a look.
Original Article: FDA Action Alert: Merck, Jazz, Regeneron, Sanofi and TherapeuticsMD